Industrial cGMP peptide production has advanced significantly, now operating at scales previously unimaginable. Today, manufacturers produce hundreds of kilograms of short-chain peptides annually to meet rising demand. This shift marks a new era of efficient production, tailored to evolving needs. A pivotal moment in this evolution was the introduction of Roche's Enfuvirtide (Fuzeon), an HIV fusion inhibitor approved by the FDA in 2003. Enfuvirtide was the first long peptide produced using convergent, large-scale manufacturing processes. Its success led to a dramatic increase in the global consumption of Fmoc-Amino acid derivatives, essential materials in peptide synthesis, causing their prices to plummet.
Inspired by Fuzeon's success, manufacturers now produce peptides in quantities reaching hundreds of kilograms to support orally administered drugs in large doses. This progress has expanded the potential for designing synthetic schemes for peptides with fifty or more amino acids, broadening their therapeutic applications. For more insights, read our whitepaper.
